What question did this study set out to answer?

To characterize the endogenous cholinergic pathway mediating angiogenesis and determine the specific role of non-neuronal nicotinic acetylcholine receptors.

August 15, 2002Journal of Clinical Investigation

A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors

View Full Paper

Ask AI

Bookmark

Authors

CHChristopher HeeschenCandiolo Cancer Institute MWMichael WeisRosa (United States)AAAlexandra AicherChina Medical University

Discussion

Member takes

Implication

Preclinical study reveals that non-neuronal nicotinic acetylcholine receptors drive angiogenesis in endothelial models, highlighting a novel therapeutic target for vascular modulation.

Key Points

To characterize the endogenous cholinergic pathway mediating angiogenesis and determine the specific role of non-neuronal nicotinic acetylcholine receptors.
Assayed endothelial cell network formation in vitro using selective and nonselective nicotinic acetylcholine receptor (nAChR) antagonists, including mecamylamine and α-bungarotoxin.
Evaluated receptor downstream signaling involving PI3K, MAPK, and NF-κB, as well as expression changes under hypoxic and ischemic conditions.
Assessed inflammatory angiogenesis, ischemia-induced angiogenesis, and tumor growth in vivo using pharmacological inhibition and α7-nAChR knockout models.
Endothelial network formation was completely and reversibly blocked by mecamylamine and specifically inhibited by the α7-nAChR antagonist α-bungarotoxin.
The angiogenic response depended completely on PI3-kinase and MAPK signaling pathways, induced NF-κB activation, and exhibited partial dependence on VEGF.
Pharmacological inhibition or genetic deletion of α7-nAChR in vivo significantly suppressed inflammatory angiogenesis, ischemia-induced vessel growth, and tumor growth.

Cite This Study

Heeschen et al. (2002) studied this question.

synapsesocial.com/papers/6a00ff04b124fe5819862ac7 https://doi.org/10.1172/jci0214676

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study reveals that non-neuronal nicotinic acetylcholine receptors drive angiogenesis in endothelial models, highlighting a novel therapeutic target for vascular modulation.

A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors

Discussion

Member takes

Implication

Key Points

Cite This Study

A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider